Comparison of the baseline clinical and US variables between patients (with a follow-up of at least 3 months) without development of PsA and those developed PsA
| PsO+PsOAr without PsA development (n=96) | PsO+PsOAr with PsA development (n=6) | P value | |
| Age, mean (±SD) | 50.23 (±15.25) | 59.17 (±8.75) | 0.15 |
| Female, n (%) | 54 (56.25 %) | 3 (50 %) | 1 |
| Smoking, n (%) | 18 (18.75 %) | 0 (0 %) | 0.62 |
| BMI, mean (±SD) | 25 (±4.29) | 28 (±3.16) | 0.08 |
| Family history of PsA, n (%) | 14 (14.74 %) | 1 (16.67 %) | 1 |
| VAS pain (0–10), mean (±SD) | 2.63 (±2.35) | 5.92 (±2.01) | <0.01 |
| HAQ, mean (±SD) | 0.26 (±0.38) | 0.44 (±0.22) | 0.03 |
| Tender joints count, mean (±SD) | 1.74 (±3.16) | 6.8 (±10.87) | 0.03 |
| Tender enthesis count, mean (±SD) | 0.29 (±0.60) | 1 (±2.45) | 0.96 |
| Active synovitis, n* (%) | 20 (20.83 %) | 2 (33.33 %) | 0.61 |
| Active synovitis, mean joint number (±SD) | 0.3 (±0.68) | 1 (±1.67) | 0.31 |
| Active enthesitis, n† (%) | 21 (21.88 %) | 4 (66.67 %) | 0.03 |
| Active enthesitis, mean entheseal number (±SD) | 0.27 (±0.55) | 0.67 (±0.52) | 0.03 |
| GS tenosynovitis, n‡ (%) | 19 (19.8%) | 1 (16.7%) | 1 |
| GS tenosynovitis, mean (±SD) | 0.41 (1.07) | 0.25 (1.22) | 0.97 |
Values in bld signifies p value ≤0.05.
*Number of patients with at least one active synovitis.
†Active enthesitis.
‡Tenosynovitis in GS.
BMI, body mass index; GS, grey scale; HAQ, Health Assessment Questionnaire; HC, healthy control; PsA, psoriatic arthritis; PsO, psoriasis alone; PsOAr, psoriasis patients with arthralgia; US, ultrasonography; VAS, Visual Analogue Scale.